Sam In Ung

PCSK9 inhibitors usage in South China: A Multi-Center Real-World Study

Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are effective for lipid management in high-risk patients with atherosclerotic cardiovascular disease. Their inclusion in China’s National Reimbursement Drug List and the Hong Kong Hospital Authority Drug Formulary...